MARKET

ABCL

ABCL

Abcellera Biologics Inc.
NASDAQ
2.630
+0.030
+1.15%
Opening 11:11 04/25 EDT
OPEN
2.560
PREV CLOSE
2.600
HIGH
2.630
LOW
2.540
VOLUME
344.23K
TURNOVER
--
52 WEEK HIGH
4.340
52 WEEK LOW
1.891
MARKET CAP
783.71M
P/E (TTM)
-4.7533
1D
5D
1M
3M
1Y
5Y
1D
3 Promising Penny Stocks With Market Caps Up To $800M
Simply Wall St · 1d ago
Weekly Report: what happened at ABCL last week (0414-0418)?
Weekly Report · 4d ago
Leerink Partners Remains a Buy on AbCellera Biologics (ABCL)
TipRanks · 04/18 13:57
ABCELLERA BIOLOGICS INC <ABCL.O>: LEERINK PARTNERS CUTS TARGET PRICE TO $5 FROM $7
Reuters · 04/17 11:08
AbCellera: Attractively Priced But A Catalyst Is Needed
Seeking Alpha · 04/17 03:59
AbCellera Biologics Price Target Raised to $5.00/Share From $4.00 by Keybanc
Dow Jones · 04/16 12:29
AbCellera Biologics Is Maintained at Overweight by Keybanc
Dow Jones · 04/16 12:29
Keybanc Maintains Overweight on AbCellera Biologics, Raises Price Target to $5
Benzinga · 04/16 12:19
More
About ABCL
More
AbCellera Biologics Inc. discovers and develops antibody medicines for indications across therapeutic areas including cancer, metabolic and endocrine conditions, and autoimmune disorders. The Company’s engine integrates technology, data science, infrastructure, and interdisciplinary teams to solve the antibody discovery problems. The Company has developed technology platforms to unlock drug classes, targets, and modalities, including transmembrane proteins, T-cell engagers, and peptide-MHCs. The Company is focused on advancing an internal pipeline of programs and collaborating on drug development programs with partners. Its first two preclinical programs in its internal pipeline are ABCL575 and ABCL635. ABCL635 is an antibody-drug candidate against an undisclosed target with an indication in metabolic and endocrine conditions. ABCL575 targets OX40 ligand and is being developed as a therapy for the treatment of atopic dermatitis and other indications of autoimmunity and inflammation.
Recently
Symbol
Price
%Change

Webull offers AbCellera Biologics Inc stock information, including NASDAQ: ABCL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ABCL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ABCL stock methods without spending real money on the virtual paper trading platform.